Skip to content
SEC EDGARcompany profilefree

Merck & Co., Inc. due diligence

Who Merck & Co., Inc. (MRK) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1011 filings in EDGAR's recent index646 of them Form 4 filingsview the filings on SEC EDGARsource: SEC EDGAR, XBRL data

At a glance

Merck & Co., Inc. (MRK) is a large accelerated filer incorporated in New Jersey, classified under SIC 2834 (Pharmaceutical Preparations), and lists on NYSE. Its fiscal year ends December 31. It has also filed as Merck & Co. Inc. and SCHERING PLOUGH CORP.

For the fiscal year ended December 31, 2025, its 10-K reported revenue of $65.0B, up 1.3% from the year before, net income of $18.3B, and total assets of $137B.

In the twelve months to November 20, 2026 it made 150 filings on EDGAR, including 1 annual report, 3 quarterly reports, 9 current reports on Form 8-K, and 81 Form 4 insider filings, plus 6 prospectus supplements and free writing prospectuses for its securities offerings. Its 8-Ks were filed most often for results of operations (4), officer or director changes (2), and other events (2).

CIK
0000310158
Filer status
Large accelerated filer
Industry (SIC)
Pharmaceutical Preparations (2834)
Incorporated
New Jersey
Listed on
NYSE
Tickers
MRK
Fiscal year end
12-31

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-31$65.0B +1.3%$18.3B +6.6%$137B
2024-12-31$64.2B +6.7%$17.1B +4589.6%$117B
2023-12-31$60.1B$365M$107B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag Revenues); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-242025-12-310000310158-26-000063
Quarterly report (10-Q)2026-11-042026-09-300000310158-26-000248
Current report (8-K)2026-11-182026-11-160000310158-26-000255

Filing activity

150 filings since 2025-11-20, 6 of them prospectus supplements and free writing prospectuses (not listed below). By form:

Form 4
81
Form 144
22
8-K
9
SC TO-T/A
5
13F-HR
4
Form 3
4
10-Q
3
11-K
3

8-K items in the last 12 months: results of operations (Item 2.02, 4) · officer or director changes (Item 5.02, 2) · other events (Item 8.01, 2) · shareholder vote results (Item 5.07, 1).

FiledFormDocumentPeriod
2026-11-188-KCurrent report on Form 8-K2026-11-16
2026-11-164Form 4 insider filing2026-11-12
2026-11-1313F-HRForm 13F-HR filing2026-09-30
2026-11-12144Form 144 notice of proposed sale
2026-11-0410-QQuarterly report2026-09-30
2026-11-034Form 4 insider filing2026-11-01
2026-11-033Form 3 initial ownership filing2026-11-01
2026-11-02144Form 144 notice of proposed sale
2026-10-298-KFORM 8-K2026-10-29
2026-10-223/AForm 3/A filing2026-05-01
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on Merck & Co., Inc.

The free view above is the filing record: identity, annual results and the last year of filings. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"MRK"} over x402 or MPP, $0.85

Sample output and API docsall reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.